The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

被引：487
|
作者：
Yuan, Min [1 ,2 ]
Huang, Li-Li [1 ,2 ]
Chen, Jian-Hua [1 ,3 ]
Wu, Jie [3 ,4 ]
Xu, Qing [1 ,2 ]
机构：
[1] Tongji Univ, Dermatol Hosp, Dept Oncol, Sch Med, Shanghai 200443, Peoples R China
[2] Tongji Univ, Shanghai Peoples Hosp 10, Dept Oncol, Sch Med, Shanghai 200072, Peoples R China
[3] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK 73104 USA
[4] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA
来源：
SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2019年 / 4卷 / 1期
基金：
中国国家自然科学基金;
关键词：
EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITORS; ANTI-HER3; MONOCLONAL-ANTIBODY; NIVOLUMAB PLUS IPILIMUMAB; RECEPTOR GENE-MUTATIONS; RANDOMIZED PHASE-III; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; EGFR MUTATIONS;
D O I：
10.1038/s41392-019-0099-9
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient's tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.
引用
收藏
页数：14
相关论文
共 50 条
  • [21] Targeted therapy for non-small-cell lung cancer: past, present and future
    Forde, Patrick M.
    Ettinger, David S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (06) : 745 - 758
  • [22] Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer
    Lau, Sally C. M.
    Batra, Ullas
    Mok, Tony S. K.
    Loong, Herbert H.
    DRUGS, 2019, 79 (08) : 823 - 831
  • [23] Dacomitinib, an emerging HER-targeted therapy for non-small cell lung cancer
    Carpenter, Richard L.
    Lo, Hui-Wen
    JOURNAL OF THORACIC DISEASE, 2012, 4 (06) : 639 - 642
  • [24] Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
    Gower, Arjan
    Wang, Yisong
    Giaccone, Giuseppe
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2014, 92 (07): : 697 - 707
  • [25] Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer
    Pabani, A.
    Butts, C. A.
    CURRENT ONCOLOGY, 2018, 25 : S94 - S102
  • [26] Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges
    Mielgo-Rubio, Xabier
    Martin, Margarita
    Remon, Jordi
    Higuera, Oliver
    Calvo, Virginia
    Jarabo, Jose Ramon
    Conde, Esther
    Luna, Javier
    Provencio, Mariano
    De Castro, Javier
    Lopez-Rios, Fernando
    Hernando-Trancho, Florentino
    Counago, Felipe
    FUTURE ONCOLOGY, 2021, 17 (30) : 4011 - 4025
  • [27] Breakthrough in targeted therapy for non -small cell lung cancer
    Ye, Zhencong
    Huang, Yongmei
    Ke, Jianhao
    Zhu, Xiao
    Leng, Shuilong
    Luo, Hui
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 133
  • [28] Targeted therapy for non-small cell lung cancer
    Glanemann, Franziska
    Wiesweg, Marcel
    ONKOLOGIE, 2024, 30 (09): : 877 - 885
  • [29] Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer
    Zhuang, Hongqing
    Zhao, Xianzhi
    Zhao, Lujun
    Chang, Joe Y.
    Wang, Ping
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 667 - 675
  • [30] Molecular alterations in non-small-cell lung cancer: Perspective for targeted therapy and specimen management for the bronchoscopist
    Czarnecka-Kujawa, Kasia
    Yasufuku, Kazuhiro
    RESPIROLOGY, 2014, 19 (08) : 1117 - 1125
12345